Business
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces
About this update from Tscan Therapeutics, Inc.
[{"type":"text","content":"Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces key leadership promotions WALTHAM, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Barbara Klencke, M.D., to its Board of Directors, effective April 6, 2023. Dr. Klencke is an accomplished oncology drug developer with a demonstrated track record of success, having made substantial contributions to the development and approval of numerous oncology products. “I am pleased to welcome Barbara, a highly respected and experienced leader in oncology, as an independent director to the TScan Board,” said Gavin MacBeath, Ph.D., acting Chief Executive Officer and Chief Scientific and Operating Officer. “As Chief Medical Officer and Chief Development Officer of a late-stage biopharmaceutical company focusing on advancing targeted therapeutics for the treatment of rare cancers, Barbara brings extensive experience that will be critical in the next phase of the Company’s growth. The addition of Dr. Klencke comes at an exciting time for our Company as we continue to deliver on our focused clinical pipeline with multiple value inflection points in solid tumors and hematologic malignancies throughout 2023. We look forward to her contributions.” “I am delighted to be joining TScan Therapeutics’ board as I share the Company’s commitment to creating life-changing T cell therapies for patients in need. I am grateful to be working alongside an accomplished team of industry veterans and look forward to contributing to the progress already underway, helping to support the advancement of the Company’s compelling scientific pipeline,” commented Dr. Klencke. Dr. Klencke is a seasoned executive with more than 20 years of experience across both pharmaceutical and biotech companies. She most recently served as the Chief Medical and Chief Development Officer of Sierra Oncology Inc., which was acquired by GlaxoSmithKline in 2022. Dr. Klencke has served as an independent board member of eFFECTOR Therapeutics, Inc. since 2021, Immune-Onc Therapeutics, Inc. since 2022,...